CLARIVATE PLC — Form 8-K
Filed July 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Clarivate Analytics (UK) Limited and Camelot U.S. Acquisition LLC agreed to sell their enriched data, analytics and technology solutions business serving pharmaceutical, biotech, medical device, healthcare provider and life sciences companies to Janus Buyer, LP (backed by Altaris Health Partners VI funds) for a base purchase price of $600M, plus working capital and cash adjustments, minus debt and transaction expenses, with a $75M seller note and $25M deferred consideration. Closing subject to regulatory approvals and other customary conditions, targeted for ~90-120 days after agreement dated July 3, 2026.
Why this rating
Moderate event: $600M base price is ~46% of Clarivate's $1.3B market cap—material but not transformational. Seller note and deferred consideration suggest partial cash at close. Standard M&A divestiture with typical reps, warranties, covenants. No going-concern risk; ordinary business restructuring relative to company size.
Extracted items
See more from July 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.